iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Raised by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lifted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 192.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,220 shares of the company's stock after acquiring an additional 55,394 shares during the period. Public Employees Retirement System of Ohio owned 0.23% of iTeos Therapeutics worth $647,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in iTeos Therapeutics during the fourth quarter valued at about $42,000. Virtus ETF Advisers LLC grew its holdings in shares of iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after purchasing an additional 3,293 shares during the period. Forefront Analytics LLC acquired a new stake in iTeos Therapeutics during the 4th quarter worth approximately $85,000. Graham Capital Management L.P. acquired a new stake in iTeos Therapeutics during the 4th quarter worth approximately $85,000. Finally, SG Americas Securities LLC raised its holdings in iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after buying an additional 1,508 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Down 0.1%

Shares of NASDAQ ITOS traded down $0.01 during trading on Friday, reaching $10.17. 1,062,628 shares of the stock were exchanged, compared to its average volume of 659,625. The company has a market capitalization of $389.25 million, a price-to-earnings ratio of -3.23 and a beta of 1.51. The business's 50-day moving average price is $7.38 and its 200 day moving average price is $7.47. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. As a group, sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ITOS has been the subject of several research reports. Wells Fargo & Company reiterated an "equal weight" rating and set a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Wedbush downgraded iTeos Therapeutics from an "outperform" rating to a "neutral" rating and increased their price target for the company from $10.00 to $12.00 in a report on Wednesday, May 28th. JPMorgan Chase & Co. lowered iTeos Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. Finally, Raymond James set a $12.00 price objective on iTeos Therapeutics in a research note on Wednesday, May 14th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $15.86.

Insider Transactions at iTeos Therapeutics

In other iTeos Therapeutics news, CEO Michel Detheux sold 8,400 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $10.10, for a total value of $84,840.00. Following the transaction, the chief executive officer now directly owns 135,903 shares of the company's stock, valued at $1,372,620.30. This represents a 5.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $8,317,363.86. Following the transaction, the insider now owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,843,142 shares of company stock valued at $15,238,020. 12.50% of the stock is currently owned by insiders.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.